Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	6.46T +69.8%
Revenue (ttm)	1.66T +12.9%
Net Income	217.04B +102.2%
EPS	17,099.54 +102.0%
Shares Out	12.69M
PE Ratio	29.77
Forward PE	29.39
Dividend	2,000.00 (0.51%)
Ex-Dividend Date	Mar 30, 2026

Volume	111,028
Open	492,500
Previous Close	509,000
Day's Range	474,500 - 500,000
52-Week Range	288,000 - 647,000
Beta	0.49
Analysts	Buy
Price Target	641,666.67 (+32.99%)
Earnings Date	Oct 29, 2026

About Hanmi Pharm.

A globally active pharmaceutical company, Hanmi Pharm. Co., Ltd. was established in Seoul, South Korea, in 1973. The firm concentrates its efforts on researching and developing medical therapies for a range of health issues, including diabetes, obesity, cancer, autoimmune disorders, and various rare diseases.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2025, Hanmi Pharm.'s revenue was 1.55 trillion, an increase of 3.48% compared to the previous year's 1.50 trillion. Earnings were 169.55 billion, an increase of 39.76%.

Analyst Summary

According to 12 analysts, the average rating for 128940 stock is "Buy." The 12-month stock price target is ₩641,667, which is an increase of 32.99% from the latest price.

Price Target

₩641,667

(32.99% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 31, 2026

Data Sources Report a data error